Regulatory Viridian wins FDA approval for Lumvoa for thyroid eye disease PharmaTimesCompany secures first commercial product with data for active and chronic TEDOphthalmologyRead full story pharminent June 29, 2026 (Last updated: June 30, 2026) PharmaTimes Company secures first commercial product with data for active and chronic TED Ophthalmology Read full story Post navigation Previous: Ipsen charts $1.75bn course for Kartos acquisitionNext: Biogen trims Apellis pipeline and R&D team after $5.6bn takeover Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026